New Kanna Elixir - Brighten Up With 20% Off
+1(855) 228-9993 (M-F, 9-6)       Email: 

ITPP (Myo-Inositol Trispyrophosphate)

Buy Our Myo-Inositol Trispyrophosphate (ITPP) Supplement


Myo-Inositol Trispyrophosphate (ITPP) is a relatively new compound that improves the ability of haemoglobin in red blood cells to release oxygen into tissues. It has the chemical formula C6H15O15P3 and the molecular weight 420.096 g/mol.


There are no products matching the selection.

ITPP Benefits and Uses


Myo-Inositol Trispyrophosphate (ITPP) is a recently discovered compound based on Myo-Inositol with significance in its ability to alter the oxygen-disassociation curve for haemoglobin in red blood cells. ITPP is of great interest to medical researchers studying the pathology of diseases related to hypoxia (low oxygen levels). Anecdotally, it may have similar effects to other energizing products.  


Where to Buy ITPP Online?


LiftMode offers a variety of unit sizes of Myo-Inositol Trispyrophosphate (ITPP), including a 1 gram sample, 2-gram (0.07 Oz), and 5 grams (0.18 Oz) unit sizes.  

All our products ship with a certificate of analysis from 3rd-party independent laboratories and all orders are covered by our 90-days refund/reshipment policy to ensure the highest quality.

Shipping restrictions: No shipping restrictions currently apply to this product and we are able to ship internationally. At checkout, the available shipping options for your location will be available.




Myo-Inositol Trispyrophosphate (ITPP) is known by a number of alternative names including:


Inositol Tripyrophosphate

Inositol 1,4,5-trisphosphate

Myo Inositol Trispyrophosphate

Sometimes confused for: Inositol Triphosphate (IT3)

[(1R,2S,3R,4R,5S,6R)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate




Scientific Consensus:


This is a relatively new product and there is very limited research on its effects and benefits in humans. Further research is necessary to fully understand the significance of its effects and adverse effects. Use with caution

DO NOT EXCEED THE RECOMMENDED SERVING SIZE. Use with caution. Do not use if pregnant or breastfeeding. 

PLEASE NOTE: ITPP is currently on the World Anti-Doping Agency list, and may NOT be used by professional athletes.




All dietary supplements have risks. Please ensure that you are familiar with the latest research on effects, side effects, benefits, and uses of a supplement before buying it.


Store in a cool, dry place. Keep out of reach of children. If you have any underlying medical conditions or are taking any medication, please consult a medical professional before using this supplement. 


These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.


buy myo-inositol trispyrophosphate itpp


How We Research Our Content

Our content is written using meticulous research methods and claims are backed by links to scientific references, wherever possible. The author and editors of Liftmode's Research Team have strong academic backgrounds in microbiology, physiology, and biochemistry.

Content Updated On: October 17, 2019




  • Duarte , C. D., Greferath , R., Nicolau , C., & Lehn, J.-M. (2010). Myo-inositol Trispyrophosphate: A Novel Allosteric Effector of Hemoglobin with High Permeation Selectivity across the Red Blood Cell Plasma Membrane. ChemBioChem, 11(18), 2543–2548. doi:10.1002/cbic.201000499

  • Lam, G., Zhao, S., Sandhu, J., Yi, R., Loganathan, D., & Morrissey, B. (2013). Detection of myo-inositol tris pyrophosphate (ITPP) in equine following an administration of ITPP. Drug Testing and Analysis, 6(3), 268–276. doi:10.1002/dta.147

  • Görgens, C., Guddat, S., Schänzer, W., & Thevis, M. (2014). Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes. Drug Testing and Analysis, 6(11-12), 1102–1107. doi:10.1002/dta.1700

  • Raykov, Z., Grekova, S. P., Bour, G., Lehn, J. M., Giese, N. A., Nicolau, C., & Aprahamian, M. (2013). Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. International Journal of Cancer, 134(11), 2572–2582. doi:10.1002/ijc.28598

  • Kieda, C., Greferath, R., Crola Da Silva, C., Fylaktakidou, K. C., Lehn, J.-M., & Nicolau, C. (2006). Suppression of hypoxia-induced HIF-1 and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes. Proceedings of the National Academy of Sciences, 103(42), 15576–15581. doi:10.1073/pnas.0607109103